Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company focused on psychiatric and neurological disorders, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026 at 3:10 p.m. EDT.
Webcast replays will be available for 90 days on the investor relations site.
Definium Therapeutics (Nasdaq: DFTX) has dosed the first patient in Ascend, its second Phase 3 pivotal study of DT120 ODT (lysergide tartrate) for major depressive disorder (MDD). The U.S. trial plans to enroll 175 participants, with topline 12-week double-blind data expected in 2027.
Ascend’s primary endpoint is change from baseline in MADRS score at Week 6 for DT120 ODT 100 µg versus placebo. The two-part design, including a 40-week open-label extension, aligns with Definium’s Emerge MDD study and Phase 3 GAD program.
Definium Therapeutics (NASDAQ:DFTX) granted inducement stock options to five new non-executive employees, covering an aggregate 255,340 common shares. The options were approved April 28, 2026, carry exercise prices equal to the grant-date closing share prices, and were issued under Nasdaq Rule 5635(c)(4) outside existing equity plans.
Vesting occurs over four years: 25% after one year, then monthly vesting over the next three years, subject to continued employment.
Definium Therapeutics (NASDAQ: DFTX) reported Q1 2026 results and program updates on May 7, 2026. Key points: three Phase 3 topline readouts for DT120 ODT are expected within ~five months; Emerge and Voyage enrollment complete; Panorama topline moved to late 3Q 2026; Ascend dosing starting in 2Q 2026.
Cash, cash equivalents and investments were $373.4 million as of March 31, 2026, which the company believes will fund operations into 2028. A company webcast was held at 4:30 p.m. EDT on May 7, 2026.
Definium Therapeutics (NASDAQ: DFTX) will report first-quarter 2026 financial results and discuss recent business highlights during a live webcast on May 7, 2026 at 4:30 p.m. EDT. The webcast covers results for the quarter ended March 31, 2026. A replay will be archived on the company's Investor Relations website for at least 30 days.
Analysts may register to participate in the Q&A; listeners are advised to join 15 minutes early.
Definium Therapeutics (Nasdaq: DFTX) outlined clinical and commercial progress for DT120 ODT (lysergide tartrate), reporting multiple near-term catalysts: three topline readouts across MDD and GAD over the next six months and a planned Phase 3 PTSD study in 2027. Key enrollment and timing updates were provided for Emerge, Ascend, Voyage, Panorama, and Haven.
Definium Therapeutics (NASDAQ:DFTX) announced inducement option grants to five newly hired non-executive employees for an aggregate of 70,860 common shares, with effective grant dates of April 6, 2026 and April 20, 2026.
The Options carry exercise prices equal to the closing share price on each grant date, vest over four years (25% after one year, then monthly over three years), were approved April 3, 2026 by the compensation committee under NASDAQ Rule 5635(c)(4), and were granted outside the company's equity incentive plans.
Definium Therapeutics (NASDAQ: DFTX) applauded the White House Executive Order signed April 18, 2026, to accelerate mental health innovation and expand access to psychedelic medical treatments.
The company said it supports a science-driven framework and is advancing a clinical development program for DT120 (lysergide tartrate) targeting GAD and MDD, and looks forward to collaboration with federal agencies and researchers.
Definium Therapeutics (NASDAQ: DFTX) announced management will participate in multiple investor events in April–May 2026, including a Needham virtual fireside chat (Apr 16), an Investor & Analyst Day in New York (Apr 22), a Needham psychedelics forum panel (Apr 27), and the RBC Global Healthcare Conference (May 19).
Audio webcasts and replays will be available on the company’s Investor Relations website for up to 90 days after each event.
Definium Therapeutics (NASDAQ:DFTX) published a retrospective study in the Journal of Mood and Anxiety Disorders showing diagnosed generalized anxiety disorder (GAD) rose from 5.4% in 2020 to 6.6% in 2023, with a three‑year cumulative prevalence of 10.3% among U.S. adults.
The analysis found annual incidence of 2.1–2.3%, a female predominance (67%), and high comorbidity with major depressive disorder, underscoring unmet treatment needs and calls for improved access and new therapies.